Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2021

View Archived Issues

First patient dosed in phase II study of ZN-c3 in uterine serous carcinoma

Vaxart's IND application for S-only oral tablet COVID-19 vaccine cleared in U.S.

Hovione Scientia describes ligand drug conjugates including BET inhibitors

Bristol Myers Squibb patents CD80/PD-L1 and/or PD-1/PD-L1 interaction inhibitors

New CDK and TRK inhibitors identified at Hangzhou Innogate Pharma

Ascentage Pharma discovers mutant GTPase KRAS inhibitors

FDA clears IND for phase I/II MARINA study of AOC-1001

Dosing begins in phase I study of mRNA-6231

Prometheus initiates phase IIa APOLLO-CD study of PRA-023 in Crohn's disease

Discovery of SR-42667: a tau-SH3 interaction inhibitor that prevents Abeta toxicity

Phase II data show safety and efficacy of OCS-02 in dry eye disease

Gem gene sparkles as ischemic stroke drug discovery target

China's NMPA approves INDs for IASO's CD19/CD22 CAR-T therapy

Collagenase clostridium histolyticum improves foot function in plantar fibromatosis study

Abcentra studies orticumab in subjects with psoriasis and cardiometabolic risk factors

Intranasal vaccination with ChAdOx1 nCoV-19 reduces viral shedding in preclinical models

ST-067 enters first-in-human study in relapsed or refractory solid tumors

Phase I trial evaluates iPSC-derived CAR T-cell therapy FT-819 for CD19+ malignancies

Phase I data with ANG-3070 pave way for phase II study in primary proteinuric kidney diseases

CTA approved in Vietnam for phase I/II/III study of SARS-CoV-2 vaccine ARCT-154

Dosing underway in phase I/II study of KRAS G12C inhibitor JAB-21822

Annovis reports interim phase II data on Posiphen in Alzheimer's and Parkinson's disease

ACD-856 shows preclinical effects on cognition, enters phase I study

FDA authorizes IND for phase I testing of Sorrento's CD38 DAR-T cell therapy candidate

Luye Pharma files IND in U.S. to study next-generation VMAT2 inhibitor LY-03015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...